Future Weight-Loss Treatments: What's Coming and What's Here Now
Several new obesity medications are advancing, but only two oral options (the Wegovy pill and orforglipron/Foundayo) are FDA-approved; retatrutide, CagriSema, and others remain investigational and are not for sale. Here is the honest map, and what you can start today.
The pipeline at a glance
New treatments are advancing fast and the headlines blur what is real. Here is what is out there, with links to our honest guide on each:
- Retatrutide — investigational triple-hormone injection, not FDA-approved or for sale.
- CagriSema — investigational; strong loss but missed a key head-to-head endpoint.
- Orforglipron (Foundayo) — FDA-approved April 2026; the first daily small-molecule GLP-1 pill.
- Oral Wegovy (the pill) — FDA-approved December 2025; the semaglutide tablet.
- The full 2026 to 2028 pipeline — our honest patient map of every drug, approved and investigational.
Be the first to know when what's next arrives
New weight-loss treatments are advancing fast. Join our free updates list and we will let you know the moment new options become available and appropriate, with no obligation.
This is a free updates list, not a purchase or a medication reservation. Investigational treatments like retatrutide are not FDA-approved and are not available for sale. We will only contact you about treatments that are actually available.
What you can start today
In the meantime, here is what a licensed clinic can actually offer now: after a one-time $119 medical review with Dr. Sharma, eligible patients begin a physician-supervised program with compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality.
Book my $119 review Read the food-noise guide
Common questions
Is retatrutide available at New Hope Weight Loss?
No. Retatrutide is investigational and has not been approved by the FDA. It is not available for sale anywhere, only through the manufacturer's clinical trials. We do offer physician-supervised compounded options today; ask us what is appropriate for you.
Can I join a waitlist for future treatments?
Yes. You can join our updates list to be notified when new treatments become available and appropriate. Joining is free and is not a purchase or a reservation of any medication.
What can I start with right now?
After a one-time $119 medical review with Dr. Sharma, eligible patients can begin a physician-supervised program with compounded semaglutide (from $166/month) or compounded tirzepatide (from $233/month). Compounded medications are not FDA-approved or brand-identical.
This page is educational and is not medical advice. Investigational medications are not FDA-approved, not for sale, and not offered at New Hope Weight Loss. Individual results vary and are not guaranteed.